Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Immunogenicity of MVA-BN Vaccine Deployed as Mpox Prophylaxis: A Prospective Cohort Study and Analysis of Transcriptomic Predictors of Response
32 Pages Posted: 16 Sep 2024
More...Abstract
Background: Since 2022, mpox has emerged as a salient global health threat, with two clades (I and II) causing outbreaks of international public health concern. The third generation smallpox vaccine modified vaccinia Ankara, manufactured by Bavarian Nordic (MVA-BN), has emerged as a key component of mpox prevention. To date, the immunogenicity of this vaccine, including determinants of response has been incompletely described, especially when MVA-BN has been administered intradermally at 1/5th the registered dose (‘fractionated dosing’), as recommended as a dose-sparing strategy.
Methods: We conducted a prospective cohort study and immunological analysis of responses to MVA-BN in patients attending a vaccination clinic in Oxford, UK. Blood samples were taken at baseline, day 14, day 28, and 28 and 90 days following a second vaccine. A sub-cohort had additional blood samples collected day 1 following their first vaccine (optional additional timepoint). We assessed IgG responses to mpox/vaccinia antigens using Luminex assay (‘MpoxPlex’), and T-cell responses using interferon-g enzyme linked immunospot and activation induced marker assay. Associations between blood transcriptomic signatures (baseline, day 1) and immunogenicity were assessed using differential expression analysis and gene set enrichment methods.
Findings: We recruited 34 participants of whom 33 received fractionated dosing. Of those without prior smallpox vaccination (n=30), 50% seroconverted by day 28, and while this increased to 89% by day 90 post second vaccination, individuals seronegative on day 28 demonstrated persistently lower responses compared to day 28 seropositive individuals. Serological response on day 28 positively correlated with of type I and II interferon signatures day one post-vaccination (n=18 samples) but negatively correlated with these signatures at baseline.
Interpretation: Baseline inflammatory states may inhibit MVA-BN serological immunogenicity by inhibiting the upregulation of MVA-induced innate immune signalling. If confirmed mechanistically these insights may inform improved vaccination strategies against mpox in diverse geographic and demographic settings.
Funding: This work is supported by funding from UKRI to the UK Monkeypox Research Consortium; Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences 2018-I2M-2- 002, the Kennedy Trust for Rheumatology Research (KENN 20 21 02), the John Climax Donation, and a Center for Cooperative Human Immunology (US NIH 5-U19AI142737-05) Infrastructure and Opportunity Fund (IOF) subaward to NMP. This research was supported by the National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre (BRC).
Declaration of Interest: NMP receives consulting fees from Infinitopes. AO is a contributor to WHO Mpox diagnostic guidance. AS is a consultant for AstraZeneca Pharmaceuticals, Calyptus Pharmaceuticals, Inc, Darwin Health, EmerVax, EUROIMMUN, F. Hoffman-La Roche Ltd, Fortress Biotech, Gilead Sciences, Granite bio., Gritstone Oncology, Guggenheim Securities, Moderna, Pfizer, RiverVest Venture Partners, and Turnstone Biologics. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work.
Ethical Approval: The study protocol was approved by the UK NHS Ethics committee (London – Surrey Borders Research REC ref 22/PR/1425). All participants provided written informed consent prior to any study procedures.
Keywords: mpox, Vaccine, MVA-BN, Transcriptomics, serology, T cell
Suggested Citation: Suggested Citation